Moleculin Biotech, Inc. (MBRX) Reports Peer-Reviewed Analysis Finds No Cardiotoxicity With Annamycin

Moleculin said a Cleveland Clinic—evaluated, peer-reviewed pooled analysis of five trials (90 patients) found no clinical or subclinical cardiotoxicity with Annamycin, even at cumulative doses above traditional anthracycline limits.Material DetailsContext by AI AnalystThis is mid-cycle validation o…